Buy Lupin with a Target Rs 1850: BofA-ML
The Q4 results were a strong beat on the back of healthy 20 per cent beat in EBITDA. Higher gross margins in Glumetza led margin growth despite higher R&D costs.
By 
| Updated:
| Updated: BofA-ML maintains buy rating on Lupin post March quarter results with a 12-month target price of Rs 1,850.
The Q4 results were a strong beat on the back of healthy 20 per cent beat in EBITDA. Higher gross margins in Glumetza led margin growth despite higher R&D costs.
"We will watch for update on US biz, Goa plant remediation, and Gavis integration in the con call," said the BofA-ML note.
The Q4 results were a strong beat on the back of healthy 20 per cent beat in EBITDA. Higher gross margins in Glumetza led margin growth despite higher R&D costs.
"We will watch for update on US biz, Goa plant remediation, and Gavis integration in the con call," said the BofA-ML note.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
